| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/17/2013 | EP2615163A1 Composition for preventing inflammations |
| 07/17/2013 | EP2615114A2 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
| 07/17/2013 | EP2615113A2 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
| 07/17/2013 | EP2615101A1 Nucleoside derivatives, synthesis methods and uses thereof for preparing anti-tumor and anti-virus medicaments |
| 07/17/2013 | EP2615100A1 Fructosylated puerarin, and preparation method therefor and use thereof |
| 07/17/2013 | EP2615099A1 Hydrous crystals of 2-o-alpha-d-glucosyl-l-ascorbic acid, powder containing hydrous crystals of 2-o-alpha -d-glucosyl-l-ascorbic acid, method for producing the hydrous crystals, method for producing the powder, use of the hydrous crystals, and use of the powder |
| 07/17/2013 | EP2615096A1 Quinoxaline compound |
| 07/17/2013 | EP2615094A2 Sesterterpene compounds and use thereof |
| 07/17/2013 | EP2615092A1 Heterocyclic amino berbamine derivatives, preparation method and use thereof |
| 07/17/2013 | EP2615091A2 Solid forms comprising 4-[9-(3S)-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9H-purin-2-ylamino]-trans-cyclohexan-1-ol, compositions thereof, and uses therewith |
| 07/17/2013 | EP2615090A1 Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors |
| 07/17/2013 | EP2615089A1 Pyrazoloquinoline compound |
| 07/17/2013 | EP2615088A1 Composition, synthesis and use of new substituted pyran and pterin compounds |
| 07/17/2013 | EP2615087A2 Phenylalanine derivatives |
| 07/17/2013 | EP2615086A1 2,4-Diaminoquinazolines for the treatment of spinal muscular atrophy |
| 07/17/2013 | EP2615085A1 Pyridyl derivatives as CFTR modulators |
| 07/17/2013 | EP2615084A1 Prostaglandin d synthase inhibitory piperidine compounds |
| 07/17/2013 | EP2614860A2 Pharmaceutical composition for the treatment of dry eye |
| 07/17/2013 | EP2614838A1 Agent for treatment of dry eye characterized by combining p2y² receptor agonist with hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y² receptor agonist and hyaluronic acid or salt thereof |
| 07/17/2013 | EP2614833A1 Scarring reducing wound treatment |
| 07/17/2013 | EP2614828A2 Low-modification biocompatible high polymer sulfhydryl-modified derivatives, cross-linked material thereof, and uses of said material |
| 07/17/2013 | EP2614827A2 Means and methods for counteracting muscle disorders |
| 07/17/2013 | EP2614826A1 Process for preparation of thiazole derivatives |
| 07/17/2013 | EP2614825A1 Process for the preparation of thiazole derivatives |
| 07/17/2013 | EP2614824A1 Therapeutic agent for pain |
| 07/17/2013 | EP2614823A1 Use of triazolylpiperidine derivatives |
| 07/17/2013 | EP2614822A2 Atorvastatin Derivatives |
| 07/17/2013 | EP2614821A1 Pharmaceutical composition for treating anxiety disorder, containing n-acetyl-l-cysteine or derivative thereof |
| 07/17/2013 | EP2614820A1 Transdermal therapeutic system with a choline esterase inhibitor |
| 07/17/2013 | EP2614818A1 Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, antipyretic- analgesic drug and proton pump inhibitor |
| 07/17/2013 | EP2614815A1 Foamable aerosol composition |
| 07/17/2013 | EP2614814A1 Methotrexate composition |
| 07/17/2013 | EP2614727A1 N-Nonanoylvanillylamine as an appetite reduction agent, as a means for generating the feeling of being full and as a mood enhancer and corresponding material mixtures, orally consumable products and method |
| 07/17/2013 | EP2614711A1 Disinfectant and/or bactericidal aqueous compositions |
| 07/17/2013 | EP2614144A1 Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection |
| 07/17/2013 | EP2614090A2 Hybrid cooperative complexes of hyaluronic acid |
| 07/17/2013 | EP2614089A1 Biotinylated polysaccharides having an antithrombotic activity and improved metabolic stability |
| 07/17/2013 | EP2614065A1 Substituted pyrazolo-quinazoline derivatives as kinase inhibitors |
| 07/17/2013 | EP2614064A1 Inhibitors of human immunodeficiency virus replication |
| 07/17/2013 | EP2614063A1 Substituted imidazopyridazines |
| 07/17/2013 | EP2614062A1 Imidazo [1, 2]pyridazin compounds and compositions as trk inhibitors |
| 07/17/2013 | EP2614061A1 Quinoline and quinoxaline derivatives as kinase inhibitors |
| 07/17/2013 | EP2614060A2 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazine for treating a beta-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof |
| 07/17/2013 | EP2614058A1 Polymorphs and salts of n- [5- [4- (5- { [(2r,6s) -2, 6 - dimethyl - 4 -morpholinyl]methyl} - 1, 3 - oxazol - 2 - yl) - 1h- inda zol-6-yl]-2- (methyloxy) - 3 - pyridinyl]methanesulfonamide |
| 07/17/2013 | EP2614054A1 Ethyne derivatives, pharmaceutical compositions and uses thereof |
| 07/17/2013 | EP2614051A2 P53-mdm2 antagonists |
| 07/17/2013 | EP2614050A1 1,5-diaryl-2-alkylpyrrole-3-substituted nitro esters, selective cox-2 inhibitors and nitric oxide donors |
| 07/17/2013 | EP2614049A1 Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes |
| 07/17/2013 | EP2614045A1 Method for producing crystalline 5-aminosalicylic acid |
| 07/17/2013 | EP2613798A1 Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients |
| 07/17/2013 | EP2613793A1 Nasal spray |
| 07/17/2013 | EP2613790A1 Laxative containing polyethylene glycol and electrolytes |
| 07/17/2013 | EP2613789A1 Sdf-1 binding nucleic acids and the use thereof in cancer treatment |
| 07/17/2013 | EP2613788A2 Boron-containing small molecules |
| 07/17/2013 | EP2613786A2 Treatment of diseases |
| 07/17/2013 | EP2613785A1 Heteroarylmethyl amides |
| 07/17/2013 | EP2613784A2 A transdermal drug administration device |
| 07/17/2013 | EP2613783A1 Methods for the treatment or prophylaxis of thrombosis or embolism |
| 07/17/2013 | EP2613782A2 Indazole derivatives useful as erk inhibitors |
| 07/17/2013 | EP2613781A1 Indazole derivatives for use in the treatment of influenza virus infection |
| 07/17/2013 | EP2613780A1 Methods for concomitant treatment of theophylline and febuxostat |
| 07/17/2013 | EP2613779A2 Conjugates of polyunsaturated fatty acids and amine-containing compounds and uses thereof |
| 07/17/2013 | EP2613778A1 Process for the production of l-carnitine tartrate |
| 07/17/2013 | EP2613777A2 Compositions comprising acidic extracts of mastic gum |
| 07/17/2013 | EP2613776A2 Composition and method for muscle repair and regeneration |
| 07/17/2013 | EP2613775A1 Novel n-hydroxy-benzamides for the treatment of cancer |
| 07/17/2013 | EP2613774A2 Novel use |
| 07/17/2013 | EP2613773A2 Airway administration of angiogenesis inhibitors |
| 07/17/2013 | EP2613772A2 Low-dose transdermal patches with high drug release |
| 07/17/2013 | EP2613769A1 Melt-extruded solid dispersions containing an apoptosis-inducing agent |
| 07/17/2013 | EP2613767A2 Compositions comprising a fatty acid oil mixture, a free fatty acid, and a statin |
| 07/17/2013 | EP2613766A2 Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin |
| 07/17/2013 | EP2613632A1 Continuous photolytic process for the preparation of vitamin d related substances |
| 07/17/2013 | EP2613630A1 Hydrogen bond forming fluoro ketolides for treating diseases |
| 07/17/2013 | EP2517700B1 Pharmaceutically acceptable cocrystals of N-[2-(7-methoxy-1-naphthyl]acetamide and methods of their preparation |
| 07/17/2013 | EP1465604B1 Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms |
| 07/17/2013 | CN1946421B Cancer treatment using viruses and camptothecins |
| 07/17/2013 | CN1668288B Compounds with antiparasitic activity and medicines containing same |
| 07/17/2013 | CN103210086A Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4 |
| 07/17/2013 | CN103210085A Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders |
| 07/17/2013 | CN103209997A High purity heparin and production method therefor |
| 07/17/2013 | CN103209987A Substituted nucleotide analogs |
| 07/17/2013 | CN103209985A Phosphonate ester derivatives and methods of synthesis thereof |
| 07/17/2013 | CN103209983A Crystalline form of 13-[(n-tert-butoxycarbonyl)-2'-o-hexanoyl-3-phenylisoserinyl]-10-deacetylbaccatin III |
| 07/17/2013 | CN103209982A Novel compound of a reverse-turn mimetic and a production method and use therefor |
| 07/17/2013 | CN103209981A Hetero ring-fused imidazole derivative having ampk activating effect |
| 07/17/2013 | CN103209980A Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy |
| 07/17/2013 | CN103209979A Therapeutic agents 976 |
| 07/17/2013 | CN103209977A Novel piperazine analogs with substituted heteroaryl groups as broad-spectrum influenza antivirals |
| 07/17/2013 | CN103209976A 1-(heterocyclic carbonyl)-2-substituted pyrrolidines |
| 07/17/2013 | CN103209968A Pluripotent stem cell cardiomyocyte differentiation-promoting agent |
| 07/17/2013 | CN103209967A Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide |
| 07/17/2013 | CN103209966A Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide |
| 07/17/2013 | CN103209964A Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| 07/17/2013 | CN103209963A 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds |
| 07/17/2013 | CN103209962A Substituted 6-amino-nicotinamides as kcnq2/3 modulators |
| 07/17/2013 | CN103209958A Prodrugs of guanfacine |
| 07/17/2013 | CN103209957A Process for preparing aminoadamantyl carbamate derivatives |
| 07/17/2013 | CN103209954A 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mglur 2/3 antagonists |
| 07/17/2013 | CN103209719A Local vascular delivery of adenosine A2A receptor agonists to reduce myocardial injury |